Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00613093 · ClinicalTrials.gov registry record · Phase 2
Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma
A Phase 2 study of Glioblastoma Multiforme and Anaplastic Glioma, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 1
- Study location
NCT00613093 is a Phase 2 study of Glioblastoma Multiforme and Anaplastic Glioma that has completed, run by Duke University. The registered enrollment target is 67 participants, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00613093, a Phase 2 study of Glioblastoma Multiforme and Anaplastic Glioma, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 1
- Study location
Study Summary
Objectives: To define role of O6-Benzylguanine (BG) in restoring Temodar (temozolomide) sensitivity in patients with Temodar-resistant malignant glioma. To further define toxicity of combo therapy using Temodar + BG.
Conditions Studied
Interventions
- DRUG Temodar and O6-Benzylguanine (BG)
Study Locations (1)
North Carolina
- Duke University Health System - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2002-10 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00613093
The ClinicalTrials.gov registry entry for NCT00613093 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (30% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which Temodar and O6-Benzylguanine (BG) is the first listed.
NCT00613093 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00613093 about?
NCT00613093 is a clinical study titled "Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma". Objectives: To define role of O6-Benzylguanine (BG) in restoring Temodar (temozolomide) sensitivity in patients with Temodar-resistant malignant glioma. To further define toxicity of combo therapy using Temodar + BG.
What is the current status of trial NCT00613093?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2002-10. Estimated completion is 2008-08.
What conditions does trial NCT00613093 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, Anaplastic Glioma.
What interventions are being tested in trial NCT00613093?
The interventions under investigation include: Temodar and O6-Benzylguanine (BG) (DRUG).
Who is sponsoring clinical trial NCT00613093?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00613093 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
RECRUITING · Phase 2
-
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.